131.87
+0(+0.00%)
Currency In USD
| Previous Close | 131.87 |
| Open | 131.87 |
| Day High | 131.87 |
| Day Low | 131.87 |
| 52-Week High | 131.98 |
| 52-Week Low | 64.09 |
| Volume | 16.04M |
| Average Volume | 3.62M |
| Market Cap | 14.05B |
| PE | -180.64 |
| EPS | -0.73 |
| Moving Average 50 Days | 129.42 |
| Moving Average 200 Days | 92.67 |
| Change | 0 |
Data not available
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
GlobeNewswire Inc.
Jan 13, 2025 11:32 AM GMT
Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and monotherapy; also approved for the treatment of schizophrenia in adults sNDA submitted to U.S. FDA for C
Intra-Cellular Therapies Settles CAPLYTA® (lumateperone) Patent Litigation with Sandoz
GlobeNewswire Inc.
Jan 10, 2025 11:30 AM GMT
BEDMINSTER, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announ
Intra-Cellular Therapies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2025 1:00 PM GMT
BEDMINSTER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announ